Zymeworks ZYME Bispecific Antibodies — Research and development collaborations (note 11)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's bispecific antibodies — research and development collaborations (note 11).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's bispecific antibodies — research and development collaborations (note 11)?
- Zymeworks (ZYME) reported bispecific antibodies — research and development collaborations (note 11) of $2M in Q4 2025.
- What does bispecific antibodies — research and development collaborations (note 11) mean?
- This metric represents the revenue recognized from strategic partnerships and collaborative agreements specifically related to the development of bispecific antibody therapeutic platforms. It reflects the company's ability to monetize its proprietary technology through external funding, milestone payments, or shared development costs with pharmaceutical partners. This figure serves as a key indicator of the commercial validation and market interest in the company's specialized biotherapeutic engineering capabilities.